EEG evidence of compensatory mechanisms in preclinical Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer’s disease and to better understand the pathophysiological processes of disease progression. Preclinical Alzheimer’s disease EEG changes would be non-invasive and cheap screening tools and could also help to predict future progression to clinical Alzheimer’s disease. However, the impact of amyloid-β deposition and neurodegeneration on EEG biomarkers needs to be elucidated. We included participants from the INSIGHT-preAD cohort, which is an ongoing single-centre multimodal observational study that was designed to identify risk factors and markers of progression to clinical Alzheimer’s disease in 318 cognitively normal individuals aged 70–85 years with a subjective memory complaint. We divided the subjects into four groups, according to their amyloid status (based on 18F-florbetapir PET) and neurodegeneration status (evidenced by 18F-fluorodeoxyglucose PET brain metabolism in Alzheimer’s disease signature regions). The first group was amyloid-positive and neurodegeneration-positive, which corresponds to stage 2 of preclinical Alzheimer’s disease. The second group was amyloid-positive and neurodegeneration-negative, which corresponds to stage 1 of preclinical Alzheimer’s disease. The third group was amyloid-negative and neurodegeneration-positive, which corresponds to ‘suspected non-Alzheimer’s pathophysiology’. The last group was the control group, defined by amyloid-negative and neurodegeneration-negative subjects. We analysed 314 baseline 256-channel high-density eyes closed 1-min resting state EEG recordings. EEG biomarkers included spectral measures, algorithmic complexity and functional connectivity assessed with a novel information-theoretic measure, weighted symbolic mutual information. The most prominent effects of neurodegeneration on EEG metrics were localized in frontocentral regions with an increase in high frequency oscillations (higher beta and gamma power) and a decrease in low frequency oscillations (lower delta power), higher spectral entropy, higher complexity and increased functional connectivity measured by weighted symbolic mutual information in theta band. Neurodegeneration was associated with a widespread increase of median spectral frequency. We found a non-linear relationship between amyloid burden and EEG metrics in neurodegeneration-positive subjects, either following a U-shape curve for delta power or an inverted U-shape curve for the other metrics, meaning that EEG patterns are modulated differently depending on the degree of amyloid burden. This finding suggests initial compensatory mechanisms that are overwhelmed for the highest amyloid load. Together, these results indicate that EEG metrics are useful biomarkers for the preclinical stage of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“The pathophysiological process of Alzheimer’s disease begins many years before the onset of symptoms (Bateman et al., 2012; Villemagne et al., 2013).”
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 2×
“Previous work in animal models has shown that intermediate levels of Aβ enhance synaptic activity presynaptically (Abramov et al. , 2009), whereas abnormally high levels of Aβ impair synaptic activity by inducing post-synaptic depression (Palop and Mucke, 2010).”
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“First, amyloid deposition alone does not necessarily represent progression to clinical Alzheimer’s disease as both neuropathological and PET data show evidence of extensive amyloid-b pathology in cognitively normal older people (Bennett et al., 2006; Morris et al., 2010; Jagust, 2016).”
Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer’s Disease
Busche, M. A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.-H., Haass, C., Staufenbiel, M., Konnerth, A., & Garaschuk, O. (2008) · Science · doi:10.1126/science.1162844 · Cited by 1,125
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
de Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629 · cited 1×
“…18 F-FDG PET showed that cerebral metabolic rate of glucose reduction predicted cognitive decline from normal elderly cognition to MCI/AD with a high accuracy, decliners showing greater reduction of 18 F-FDG SUVR values (de Leon et al. , 2001; Jagust et al. , 2006; Mosconi et al. , 2009, 2010).”
Sitt, J. D., King, J.-R., El Karoui, I., Rohaut, B., Faugeras, F., Gramfort, A., Cohen, L., Sigman, M., Dehaene, S., & Naccache, L. (2014) · Brain · doi:10.1093/brain/awu141 · Cited by 608 · cited 5×
“…state rhythms are typically observed at theta and alpha frequencies and these rhythms show maximum changes in AD patients (Blinowska et al. , 2017); moreover, wSMI was shown to better discriminate between different states of consciousness in the theta band (King et al. , 2013; Sitt et al. , 2014).”
InfluentialSelf-citationJack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“Moreover, very few studies of early stages of Alzheimer’s disease consider neurodegeneration information when selecting subjects, whereas it has been suggested that studies combining an abnormal amyloid biomarker with an abnormal neurodegeneration biomarker provide much more powerful prediction of future cognitive dec…”
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Amariglio, R. E., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2031 · Cited by 328
Brain imaging evidence of preclinical Alzheimer's disease in normal aging
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006) · Annals of Neurology · doi:10.1002/ana.20799 · Cited by 222 · cited 1×
“…18 F-FDG PET showed that cerebral metabolic rate of glucose reduction predicted cognitive decline from normal elderly cognition to MCI/AD with a high accuracy, decliners showing greater reduction of 18 F-FDG SUVR values (de Leon et al. , 2001; Jagust et al. , 2006; Mosconi et al. , 2009, 2010).”
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., Rabinovici, G. D., & Jagust, W. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4013 · Cited by 171 · cited 1×
“Moreover, very few studies of early stages of Alzheimer’s disease consider neurodegeneration information when selecting subjects, whereas it has been suggested that studies combining an abnormal amyloid biomarker with an abnormal neurodegeneration biomarker provide much more powerful prediction of future cognitive dec…”
BABILONI, C., FRISONI, G., PIEVANI, M., VECCHIO, F., LIZIO, R., BUTTIGLIONE, M., GEROLDI, C., FRACASSI, C., EUSEBI, F., & FERRI, R. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.08.005 · Cited by 171 · cited 1×
“A decrease of alpha coherence, an increase of delta total coherence and an abnormal alpha fronto-parietal coupling have been described in AD (Jelic et al. , 2000; Babiloni et al. , 2009).”
Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
Nakamura, A., Cuesta, P., Fernández, A., Arahata, Y., Iwata, K., Kuratsubo, I., Bundo, M., Hattori, H., Sakurai, T., Fukuda, K., et al. (2018) · Brain · doi:10.1093/brain/awy044 · Cited by 151
Is amyloid-β harmful to the brain? Insights from human imaging studies
Jagust, W. (2016) · Brain · doi:10.1093/brain/awv326 · Cited by 110
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89 · cited 1×
“Moreover, very few studies of early stages of Alzheimer’s disease consider neurodegeneration information when selecting subjects, whereas it has been suggested that studies combining an abnormal amyloid biomarker with an abnormal neurodegeneration biomarker provide much more powerful prediction of future cognitive dec…”
Dottori, M., Sedeño, L., Martorell Caro, M., Alifano, F., Hesse, E., Mikulan, E., García, A. M., Ruiz-Tagle, A., Lillo, P., Slachevsky, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04204-8 · Cited by 73
Cited by
The inter-relationship between delirium and dementia: the importance of delirium prevention
Fong, T. G., & Inouye, S. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00698-7 · Cited by 404
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Biomarkers of neurodegeneration across the Global South
McGlinchey, E., Duran-Aniotz, C., Akinyemi, R., Arshad, F., Zimmer, E. R., Cho, H., Adewale, B. A., & Ibanez, A. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00132-6 · Cited by 32
Structural inequality and temporal brain dynamics across diverse samples
Baez, S., Hernandez, H., Moguilner, S., Cuadros, J., Santamaria‐Garcia, H., Medel, V., Migeot, J., Cruzat, J., Valdes‐Sosa, P. A., Lopera, F., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70032 · Cited by 21
Metadata
- Authors
- Gaubert, S., Raimondo, F., Houot, M., Corsi, M.-C., Naccache, L., Diego Sitt, J., Hermann, B., Oudiette, D., Gagliardi, G., Habert, M.-O., Dubois, B., De Vico Fallani, F., Bakardjian, H., Epelbaum, S., & Initiative, A. D. N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06-18
- Volume
- 142
- Issue
- 7
- Pages
- 2096-2112
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2952277065
- Cited by
- 235
- References
- 26
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.